EUVIMEDEUVIMED entdecken
Crossref

Carbonic anhydrase IX inhibition as a path to treat neuroblastoma

Agne Petrosiute, Audrius Zakšauskas, Asta Lučiūnaitė, Vytautas Petrauskas, Lina Baranauskienė, Agnė Kvietkauskaitė, Alvilė Ščerbavičienė, Marta Tamošiūnaitė, Justina Musvicaitė, Alberta Jankūnaitė, Gediminas Žvinys, Laimonas Stančaitis und 10 weitere

British Journal of Pharmacology · 2025-04 · 182 (7) · 1610-1629

DOI: 10.1111/bph.17429 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 07.01.2025. Verfasst von Agne Petrosiute und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania. Hauptthemen laut MEDLINE: Neuroblastoma, Carbonic Anhydrase IX, Carbonic Anhydrase Inhibitors, Antigens, Neoplasm. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: Lithuanian Central Project Management Agency, St. Baldrick's Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Tumour hypoxia frequently presents a major challenge in the treatment of neuroblastoma (NBL). The neuroblastoma cells produce carbonic anhydrase IX (CA IX), an enzyme crucial for the survival of cancer cells in low‐oxygen environments. Experimental Approach We designed and synthesised a novel high‐affinity inhibitor of CA IX. The highest to‐date. The affinities were determined for all human catalytically active CA isozymes showing significant selectivity for CA IX over other isozymes. The inhibitor effect on neuroblastoma cancer cell growth was determined in vitro and in vivo via a mice xenograft model. Key Results The novel designed inhibitor effectively mitigated the acidification induced by CA IX and reduced spheroid growth under hypoxic conditions in the SK‐N‐AS cell line. It also diminished the secretion of pro‐tumour chemokines IL‐8 (CXCL2) and CCL2. When we combined this novel CA IX inhibitor with a compound that inhibits the chemokine receptor CCR2 protein activity, we observed a reduction in mouse tumour growth. The combined treatment also prompted tumours to exhibit adaptive resistance by producing higher levels of vascular endothelial growth factor receptors (VEGFR) and other compensatory signals. Conclusions and Implications This research underscores the pivotal role of CA IX in cancer and the potential of a novel CA IX inhibitor‐based combination intervention therapy for neuroblastoma treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaCarbonic Anhydrase IXCarbonic Anhydrase InhibitorsAntigens, NeoplasmAntineoplastic AgentsHumansAnimalsCell Line, TumorMiceXenograft Model Antitumor AssaysFemaleCell ProliferationMice, Nude

Stichwörter der Autor:innen

cancer therapycarbonic anhydrase IXinhibitor of CA IXneuroblastomathermal shift assaytumour hypoxia

Substanzen

Carbonic Anhydrase IXCarbonic Anhydrase InhibitorsCA9 protein, humanAntigens, NeoplasmAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
  • Department of Immunology, Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
  • Department of Biological Models, Institute of Biochemistry, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
  • Functional Pharmacology and Neuroscience, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.

ORCID-Profile: Daumantas Matulis

Förderung

  • Lithuanian Central Project Management Agency
  • St. Baldrick's Foundation

Zitieren

APA

Petrosiute, A., Zakšauskas, A., Lučiūnaitė, A., Petrauskas, V., Baranauskienė, L., Kvietkauskaitė, A., Ščerbavičienė, A., Tamošiūnaitė, M., Musvicaitė, J., Jankūnaitė, A., Žvinys, G., Stančaitis, L., Čapkauskaitė, E., Mickevičiūtė, A., Juozapaitienė, V., Dudutienė, V., Zubrienė, A., Grincevičienė, Š., Bukelskienė, V., …, & Matulis, D. (2025). Carbonic anhydrase IX inhibition as a path to treat neuroblastoma. British Journal of Pharmacology, 182(7), 1610-1629. https://doi.org/10.1111/bph.17429

Vancouver

Petrosiute A, Zakšauskas A, Lučiūnaitė A, Petrauskas V, Baranauskienė L, Kvietkauskaitė A, et al. Carbonic anhydrase IX inhibition as a path to treat neuroblastoma. British Journal of Pharmacology. 2025;182(7):1610-1629. doi:10.1111/bph.17429

BibTeX
@article{Petrosiute2025,
  author = {Petrosiute, Agne and Zakšauskas, Audrius and Lučiūnaitė, Asta and Petrauskas, Vytautas and Baranauskienė, Lina and Kvietkauskaitė, Agnė and Ščerbavičienė, Alvilė and Tamošiūnaitė, Marta and Musvicaitė, Justina and Jankūnaitė, Alberta and Žvinys, Gediminas and Stančaitis, Laimonas and Čapkauskaitė, Edita and Mickevičiūtė, Aurelija and Juozapaitienė, Vaida and Dudutienė, Virginija and Zubrienė, Asta and Grincevičienė, Švitrigailė and Bukelskienė, Virginija and Schiöth, Helgi B and Matulienė, Jurgita and Matulis, Daumantas},
  title = {Carbonic anhydrase IX inhibition as a path to treat neuroblastoma},
  journal = {British Journal of Pharmacology},
  year = {2025},
  volume = {182},
  number = {7},
  pages = {1610--1629},
  doi = {10.1111/bph.17429}
}
Kostenlos starten →